Setback for Gilead hep C candidate
February 20, 2012Research and Development, Sales and Marketing ELECTRON, GS-7977, Gilead, Pharmasset
Gilead’s investigational hepatitis C drug has been dealt a blow after patients suffer relapses in a mid-stage trial. In the …
Shortages likely as Sandoz’s Canadian plant woes continue
February 20, 2012Manufacturing and Production FDA, Novartis, Sandoz
Ongoing compliance problems at a plant in Canada operated by Novartis’ generics subsidiary Sandoz look set to cause supply disruptions …
Pfizer closes in on $545m China generics deal
February 20, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing China, Hisun, Pfizer, Zhejiang, generics
Pfizer has moved a step closer to a deal with Shanghai-based Zhejiang Hisun Pharmaceutical to develop generic drugs in China. …
Health Information appoints Nigel Brooksby as its deputy chairman
February 20, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, Brooksby, Health Information
Health Information, a provider of medicine adherence services in the UK, has appointed former ABPI president Nigel Brooksby as its …
European approval for Roche’s Zelboraf
February 20, 2012Sales and Marketing Cancer, Roche, Yervoy, Zelboraf, melanoma
Roche’s skin cancer pill Zelboraf has been given European approval to treat advanced melanoma. Zelboraf (vemurafenib) is now available in …
GSK pulls Tyverb extension in Europe
February 17, 2012Sales and Marketing GSK, Herceptin, Tyverb, Xeloda
GlaxoSmithKline has withdrawn its European application to extend the licence of its breast cancer pill Tyverb. The firm was seeking …
UCB releases ‘Epilepsy In Our Time’ video diaries
February 17, 2012Medical Communications UCB, epilepsy
UCB has released Epilepsy In Our Time, a video diary that explores life with epilepsy from the perspective of those …
Life tops up its team with two new appointments
February 17, 2012Medical Communications Life healthcare communications
Life Healthcare Communications has made two new appointments, growing its client service and production departments. Matt Leeming joins Life as …
NICE no for first line Tarceva
February 17, 2012Sales and Marketing CDF, Cancer, NICE, Roche, Tarceva
NICE no for first line Tarceva Watchdog wants more information on Roche’s drug NICE is not recommending Roche’s lung cancer …
Merck unveils Brazilian joint venture
February 17, 2012Sales and Marketing Brazil, Merck & Co, Supera Farma, emerging markets
Merck Inc has bolstered its presence in emerging markets by entering a joint venture with Brazilian firm Supera Farma Laboratorios. Due …
Cimzia results excite UCB in psoriatic arthritis
February 16, 2012Research and Development, Sales and Marketing Cimzia, UCB, psoriatic arthritis
UCB will submit Cimzia for psoriatic arthritis by the end of 2012, after positive Phase III trial results for the …
Words – the most powerful drug
February 16, 2012Medical Communications
Why good internal communication within organisations is essential in these fraught timesBy William Hind, Founder – AlpharmaximThe precise quote by …
Panu Miettinen appointed chief financial officer of Biotie
February 16, 2012Business Services, Research and Development, Sales and Marketing Biotie, Panu Miettinen
Panu Miettinen, 43, has been appointed chief financial officer of Biotie Therapies. He will become a member of the Group’s …
EMA appoints new head of information and communications technology
February 16, 2012Business Services, Medical Communications, Sales and Marketing EMA, Luc Verhelst
Luc Verhelst has been appointed as the new head of the European Medicines Agency’s information and communications technology unit. Verhelst …
MRN launches online training portal
February 16, 2012Research and Development
16 February 2012 – Medical Research Network (MRN), the unique Clinical Trial Support Organisation (CTSO) offering home trial support, site …
NICE frowns on Botox for headache prevention
February 16, 2012Sales and Marketing Allergan, Botox, EMA, NHS, NICE
NICE is not recommending Allergan’s Botox for headache prevention, and has asked the firm for more information on the drug. …
Amgen appoints Michael Severino as senior vice president, Global Development and Corporate chief medical officer
February 16, 2012Business Services, Research and Development, Sales and Marketing
Michael Severino has been named senior vice president, Global Development and Corporate chief medical officer at Amgen.Severino, 46, formerly vice president, …
Teva launches generic Aricept in the UK
February 16, 2012Manufacturing and Production, Sales and Marketing Alzheimer's, Aricept, NHS, Pfizer, Teva
Teva has launched its generic version of Alzheimer’s drug Aricept, as the drug loses its patent protection in the UK. …
Emerging markets no haven from HTA, says NICE
February 15, 2012Andrew Witty, GSK, NICE, NICE International
The head of NICE says pharma will face health technology assessment barriers in every country – including fast-growing developing markets. …
Most patients happy with hospital care
February 15, 2012Sales and Marketing NHS, hospital, patient survey
A new survey has found that the vast majority of NHS patients receiving outpatient hospital care are happy with the …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
